Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA

Ram I. Mahato, Kun Cheng, Ramareddy Guntaka

Research output: Contribution to journalReview article

55 Citations (Scopus)

Abstract

Antisense oligodeoxynucleotides, triplex-forming oligodeoxynucleotides and double-stranded small interfering RNAs have great potential for the treatment of many severe and debilitating diseases. Concerted efforts from both industry and academia have made significant progress in turning these nucleic acid drugs into therapeutics, and there is already one FDA-approved antisense drug in the clinic. Despite the success of one product and several other ongoing clinical trials, challenges still exist in their stability, cellular uptake, disposition, site-specific delivery and therapeutic efficacy. The principles, strategies and delivery consideration of these nucleic acids are reviewed. Furthermore, the ways to overcome the biological barriers are also discussed so that therapeutic concentrations at their target sites can be maintained for a desired period.

Original languageEnglish (US)
Pages (from-to)3-28
Number of pages26
JournalExpert Opinion on Drug Delivery
Volume2
Issue number1
DOIs
StatePublished - Jan 1 2005

Fingerprint

Oligodeoxyribonucleotides
Small Interfering RNA
Gene Expression
Nucleic Acids
Double-Stranded RNA
Pharmaceutical Preparations
Industry
Therapeutics
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA. / Mahato, Ram I.; Cheng, Kun; Guntaka, Ramareddy.

In: Expert Opinion on Drug Delivery, Vol. 2, No. 1, 01.01.2005, p. 3-28.

Research output: Contribution to journalReview article

@article{c116fdac4f334a04bdb24090ac2795b9,
title = "Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA",
abstract = "Antisense oligodeoxynucleotides, triplex-forming oligodeoxynucleotides and double-stranded small interfering RNAs have great potential for the treatment of many severe and debilitating diseases. Concerted efforts from both industry and academia have made significant progress in turning these nucleic acid drugs into therapeutics, and there is already one FDA-approved antisense drug in the clinic. Despite the success of one product and several other ongoing clinical trials, challenges still exist in their stability, cellular uptake, disposition, site-specific delivery and therapeutic efficacy. The principles, strategies and delivery consideration of these nucleic acids are reviewed. Furthermore, the ways to overcome the biological barriers are also discussed so that therapeutic concentrations at their target sites can be maintained for a desired period.",
author = "Mahato, {Ram I.} and Kun Cheng and Ramareddy Guntaka",
year = "2005",
month = "1",
day = "1",
doi = "10.1517/17425247.2.1.3",
language = "English (US)",
volume = "2",
pages = "3--28",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA

AU - Mahato, Ram I.

AU - Cheng, Kun

AU - Guntaka, Ramareddy

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Antisense oligodeoxynucleotides, triplex-forming oligodeoxynucleotides and double-stranded small interfering RNAs have great potential for the treatment of many severe and debilitating diseases. Concerted efforts from both industry and academia have made significant progress in turning these nucleic acid drugs into therapeutics, and there is already one FDA-approved antisense drug in the clinic. Despite the success of one product and several other ongoing clinical trials, challenges still exist in their stability, cellular uptake, disposition, site-specific delivery and therapeutic efficacy. The principles, strategies and delivery consideration of these nucleic acids are reviewed. Furthermore, the ways to overcome the biological barriers are also discussed so that therapeutic concentrations at their target sites can be maintained for a desired period.

AB - Antisense oligodeoxynucleotides, triplex-forming oligodeoxynucleotides and double-stranded small interfering RNAs have great potential for the treatment of many severe and debilitating diseases. Concerted efforts from both industry and academia have made significant progress in turning these nucleic acid drugs into therapeutics, and there is already one FDA-approved antisense drug in the clinic. Despite the success of one product and several other ongoing clinical trials, challenges still exist in their stability, cellular uptake, disposition, site-specific delivery and therapeutic efficacy. The principles, strategies and delivery consideration of these nucleic acids are reviewed. Furthermore, the ways to overcome the biological barriers are also discussed so that therapeutic concentrations at their target sites can be maintained for a desired period.

UR - http://www.scopus.com/inward/record.url?scp=12344283777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12344283777&partnerID=8YFLogxK

U2 - 10.1517/17425247.2.1.3

DO - 10.1517/17425247.2.1.3

M3 - Review article

VL - 2

SP - 3

EP - 28

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 1

ER -